Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06397313
Other study ID # POTAMI-61
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date September 2024
Est. completion date October 2027

Study information

Verified date June 2024
Source Ryvu Therapeutics SA
Contact Head of Clinical Operations
Phone +48-538-898-766
Email clinicaltrials@ryvu.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this clinical trial is to evaluate the efficacy (how well the drug works), safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the study drug, RVU120, in treating adult patients with intermediate or high-risk, primary or secondary myelofibrosis. RVU120 will be given as a single agent or in combination with ruxolitinib.


Description:

The study schedule consists of a screening period up to 28 days, a 21-day treatment period, an end of treatment visit (30 days) and a 1-year follow-up where participants will be contacted every 3 months for assessment. Study duration for each participant will vary depending on the number of 21-day treatment cycles received. The study is open to participants aged ≥18 years with intermediate or high-risk, primary or secondary MF who have been previously treated, are ineligible for, or had a suboptimal response to JAK inhibitor therapy. Participants must have adequate organ function (kidney, liver) and no history of hematopoietic stem cell transplant. Participants may withdraw from the study at any time at their own request or may be withdrawn at any time at the discretion of the Investigator.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 230
Est. completion date October 2027
Est. primary completion date June 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Age =18 years 2. Diagnosis of Primary or Secondary myelofibrosis (MF) according to the revised World Health Organization (WHO) criteria (Arber 2022). 3. Intermediate or high-risk disease. 4. Resistant or refractory to prior Janus kinase (JAK) inhibitor treatment or ineligible for JAK inhibitor treatment in the opinion of the investigator; or Suboptimal response to JAK inhibitor treatment. Note: a suboptimal response to JAK inhibitor treatment is defined as spleen size increase by palpation >25% after the first 3 months of treatment with a JAK inhibitor or persistent splenomegaly (spleen volume of >450 cm3) after at least 6 months of JAK inhibitor treatment and presence of 1 symptom score =5 or 2 symptom scores =3, new or persistent red blood cell (RBC) transfusion dependence; or may include participants naïve to previous treatment with JAK inhibitor. 5. Measurable splenomegaly as demonstrated by palpable spleen measuring =5 cm below the left costal margin. The edge of the spleen should be measured from the mid-clavicular line on the left side of the abdomen to the point of greatest splenic protrusion; or spleen volume of =450 cm3 measured by magnetic resonance imaging(MRI) or computed tomography (CT). 6. Active symptoms of MF as demonstrated by a symptom score of at least 5 points (on a 0 to 10 scale) on at least one of the symptoms or a score of 3 or greater on at least 2 of the following symptoms: night sweats, itchiness, abdominal discomfort, pain under ribs on left side, early satiety, bone or muscle pain, and inactivity. 7. Eastern Cooperative Oncology Group (ECOG) performance score 0-2. 8. Adequate hematologic function defined as: 1. absolute neutrophil count (ANC) =1.0 × 109/L (without growth factor support) 2. platelet count =50 × 109/L (Cohort 2 and Cohort 3 only) 9. Adequate renal function defined as calculated or measured creatinine clearance (CrCl) of =30 mL/minute using the formula of Cockcroft and Gault (see Section 15). 10. Adequate liver function defined as (a) aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =3 × upper limit of normal (ULN); (b) alkaline phosphatase (ALP) =2 × ULN (ALP =5 × ULN for participants with isozymes specific to bone); (c) bilirubin <2 × ULN or bilirubin =3 × ULN if due to Gilbert's disease. Exclusion Criteria: Each participant must not meet any of the following: 1. Peripheral blood blast count of =10% or bone marrow blast count of =10%. 2. Prior history of hematopoietic stem cell transplant. 3. Participation in any other study in which receipt of an investigational new drug occurred within 4 weeks prior to Cycle 1 Day 1. 4. Active known second malignancy with the exception of any of the following: 1. Adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer 2. Adequately treated Stage I cancer from which the participant is currently in remission and has been in remission for =2 years 3. Low-risk prostate cancer with a Gleason score <7 and a prostate-specific antigen (PSA) level <10 ng/mL 4. Any other cancer from which the participant has been disease-free for =3 years. 5. Known or suspected allergy to RVU120 or RUX. 6. Impairment of gastrointestinal function or gastrointestinal disease 7. Major surgical procedure or significant traumatic injury within 28 days Placement of a vascular access device or minor surgery is permitted within 14 days before Cycle 1 Day 1 (provided that the wound has healed). 8. Ongoing systemic infection requiring antibiotic, antiviral, or antifungal treatment. Note: prophylactic treatment is allowed. 9. Significant cardiac dysfunction defined as myocardial infarction within 12 months of Cycle 1 Day 1, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled dysrhythmias, poorly controlled angina (Section 17), or left ventricular ejection fraction (LVEF) <40% as per echocardiography or multiple gated acquisition (MUGA) scan. 10. Taking any medications, herbal supplements, or other substances (including smoking) 11. History of ventricular arrhythmia, or QTc =470 millisecond (Bazett's formula). 12. Known active human immunodeficiency virus (HIV) infection 13. Current active liver disease from any cause 14. Pregnant or lactating females. 15. Any other prior or current medical or psychiatric condition, intercurrent illness, surgical history, physical or electrocardiogram (ECG) findings, laboratory abnormalities, or extenuating circumstance (e.g., alcohol or drug addiction) that, in the Investigator's opinion, could jeopardize participant safety or interfere with the objectives of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
RVU120
RVU120 is a potent, selective inhibitor of CDK8 and its paralog CDK19
Ruxolitinib
Ruxolitinib is a kinase inhibitor which inhibits Janus Associated Kinases (JAKs) JAK1 and JAK2

Locations

Country Name City State
Italy Policlinico Sant'Orsola-Malpighi Bologna
Italy Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia Brescia
Italy Azienda Ospedaliero Universitaria Policlinico "G. Rodolico - San Marco" Catania
Italy Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. Meldola
Italy Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano
Poland Wojewódzki Szpital Specjalistyczny w Bialej Podlaskiej Biala Podlaska
Poland Szpital Uniwersytecki nr 2 im. dr Jana Biziela Bydgoszcz
Poland Centrum Wsparcia Badan Klinicznych UCK Osrodek Badan Klinicznych Wczesnych Faz Gdansk
Poland M2M Med. Sp. z o.o. Sp. j. Katowice
Poland Pratia Hematologia Sp. z o.o. Katowice
Poland Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej Kielce
Poland Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie Krakow
Poland Samodzielny Publiczny Szpital Kliniczny Nr 1 w Lublinie Lublin
Poland Wojewódzki Szpital Zespolony im. L. Rydygiera w Toruniu Torun
Poland Lux Med Onkologia Sp. z o.o. Warszawa
Poland Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy Warszawa
Poland Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu Wroclaw
Poland Szpital Uniwersytecki Imienia Karola Marcinkowskiego w Zielonej Gorze Sp. z o. o. Zielona Góra

Sponsors (1)

Lead Sponsor Collaborator
Ryvu Therapeutics SA

Countries where clinical trial is conducted

Italy,  Poland, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the number of participants with a response (anti-cancer activity) to RVU120 when administered as a single agent or in combination with ruxolitinib The proportion of participants with spleen volume reduction (SVR) of =35% after 24 weeks of study treatment evaluated by magnetic resonance imaging (MRI) or computed tomography (CT) 12 months
Secondary To further evaluate the number of participants having a response (anti-cancer activity and/or clinical benefit) to RVU120 when administered as a single agent or in combination with ruxolitinib The proportion of participants with =1 Grade bone marrow fibrosis improvement after 24 weeks of study treatment 12 months
Secondary Duration of spleen response Assessed as the time from initial SVR of =35% by MRI/CT until disease progression or death, whichever occurs first 12 months
Secondary Number of participants with leukemic transformation Assessed as the proportion of participants with bone marrow blast counts of at least 20%, or peripheral blast counts of at least 20% lasting 2 weeks 12 months
Secondary Number of participants with hematological (clinical) improvement Assessed as the proportion of participants with hematological (clinical) improvement as defined by International Working Group (IWG) Consensus Criteria (see Tefferi et al., 2006 for further details) 12 months
Secondary Progression-Free Survival (PFS) Assessed as time from the time from first treatment to the first occurrence of disease progression or death 12 months
Secondary Overall Survival (OS) Assessed as time from the time from first treatment to death 12 months
Secondary Incidence and severity of adverse events (AEs) Assessed as the number and grade of adverse events assessed by CTCAE v5.0 12 months
Secondary Change in symptom burden Assessed as the proportion of participants achieving at least a 50% reduction in symptom burden after 24 weeks of commencing study treatment as assessed by the Total Symptom Score (TSS) using the Myelofibrosis Symptom Assessment Form (MFSAF). Each item is rated on a scale from 0 (Absent) to 10 (Worst Imaginable). Baseline and week 24
Secondary Absolute change in TSS from baseline Assessed as the number of participants with absolute change in Total Symptom Score (TSS) from baseline assessed using the Myelofibrosis Symptom Assessment Form (MFSAF). Each item is rated on a scale from 0 (Absent) to 10 (Worst Imaginable). Baseline and week 24
See also
  Status Clinical Trial Phase
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Not yet recruiting NCT06345495 - High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly Phase 2
Terminated NCT04866056 - Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. Phase 1/Phase 2
Completed NCT02784496 - Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis Phase 2
Completed NCT00069680 - Genetic Analysis of Gray Platelet Syndrome
Active, not recruiting NCT04097821 - Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients Phase 1/Phase 2
Active, not recruiting NCT03289910 - Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia Phase 2
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Not yet recruiting NCT06024915 - A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets Phase 1
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Completed NCT02910258 - Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis
Completed NCT00997386 - Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States Phase 2
Completed NCT00975975 - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Phase 2
Completed NCT00666549 - Research Tissue Bank
Terminated NCT00522990 - Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias Phase 1/Phase 2
Terminated NCT00393380 - Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor Phase 2
Completed NCT00606437 - Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants Phase 1
Active, not recruiting NCT03952039 - An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib Phase 3
Not yet recruiting NCT04709458 - Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis Phase 1
Recruiting NCT04988815 - Ropeginterferon Alfa 2b for Early Myelofibrosis Phase 2